bronchiectasi
increasingli
recognis
respiratori
condit
limit
therapeut
option
complex
spectrum
clinic
manifest
invari
includ
chronic
cough
primari
present
bronchiectasi
case
chronic
cough
mechanist
underpin
central
import
remain
poorli
understood
set
bronchiectasi
also
increasingli
identifi
underli
caus
chronic
cough
highlight
interrelationship
two
condit
share
overlap
clinic
featur
sever
therapeut
approach
illustr
posit
effect
bronchiectasisassoci
cough
howev
focus
treatment
heterogen
cough
subtyp
may
yield
better
outcom
patient
current
challeng
identif
bronchiectasi
cough
endophenotyp
may
allow
improv
patient
stratif
target
therapeut
match
right
treatment
right
patient
discuss
complex
diseas
phenotyp
bronchiectasi
interrelationship
cough
consid
current
emerg
treatment
option
discuss
key
cough
promot
bronchiectasi
includ
infect
allergi
immun
dysfunct
bronchiectasi
increasingli
recognis
respiratori
syndrom
defin
perman
irrevers
dilat
bronchi
cole
viciou
cycl
remain
central
model
diseas
pathogenesi
wherebi
selfperpetu
cycl
infect
inflamm
precipit
damag
bronchial
wall
lead
impair
mucociliari
clearanc
predisposit
recurr
infect
primari
clinic
present
bronchiectasi
includ
chronic
cough
recurr
respiratori
infect
respons
increas
inflamm
airway
damag
short
breath
eventu
lung
function
declin
respiratori
failur
death
increas
awar
diseas
heterogen
includ
presenc
overlap
syndrom
brought
renew
focu
upon
potenti
underli
molecular
endophenotyp
may
better
defin
specif
diseas
trait
subtyp
amen
treatment
endotyp
repres
diseas
present
characteris
distinct
function
pathobiolog
mechan
critic
clinic
phenotyp
demonstr
multipl
endotyp
singl
endotyp
may
present
one
clinic
phenotyp
inher
diseas
heterogen
geograph
variabl
recognis
major
barrier
success
clinic
trial
question
remain
better
stratifi
patient
target
therapi
improv
clinic
outcom
recent
exampl
failur
reproduc
find
two
replic
clinic
trial
recruit
geograph
differ
region
recruit
patient
europ
north
south
america
australia
japan
focus
asian
eastern
european
addit
modest
benefit
direct
pathogendrug
treatment
observ
appear
contrast
expect
cole
viciou
cycl
hypothesi
like
reflect
complex
diseas
infect
one
mani
pulmonari
extrapulmonari
aetiolog
environment
factor
influenc
diseas
newer
emerg
model
viciou
vortex
propos
flume
colleagu
perhap
offer
complet
pictur
diseas
pathogenesi
improv
patient
stratif
identifi
diseas
endophenotyp
respond
optim
therapi
becom
key
focu
current
bronchiectasi
research
work
publish
pathophysiolog
cough
phenotyp
drive
factor
bronchiectasi
remain
well
defin
although
cough
import
lung
homeostasi
irrit
microb
caus
inflamm
aberrantli
prime
neuroimmun
pathway
lead
excess
cough
tissu
damag
process
requir
detail
studi
bronchiectasi
identif
specif
cough
phenotyp
bronchiectasi
would
provid
scope
potenti
coughdirect
intervent
understand
complex
diseas
without
current
licens
therapi
half
case
remain
idiopath
small
signific
proport
chronic
cough
attribut
bronchiectasi
almost
patient
bronchiectasi
present
persist
cough
parallel
chronic
product
cough
import
clinic
manifest
bronchiectasi
first
recognis
symptom
mani
case
anteced
confirmatori
diagnosi
given
central
import
diagnosi
patholog
bronchiectasi
clearer
understand
mechanist
underpin
desir
import
cough
bronchiectasi
illustr
implement
leicest
cough
questionnair
lcq
measur
cough
symptom
valid
bronchiectasi
correl
diseas
sever
reflect
underli
associ
cough
diseas
progress
recent
evid
corrobor
find
highlight
object
monitor
cough
frequenc
import
predictor
sputum
product
exacerb
though
lung
function
bronchiectasi
inde
import
cough
specif
cough
hypersensit
advanc
treatabl
trait
bronchiectasi
propos
potenti
target
individualis
therapi
allevi
cough
particularli
symptomat
individu
therapi
use
antituss
inhal
corticosteroid
ic
chest
physiotherapi
may
therefor
allevi
symptom
individu
problemat
cough
appropri
target
bronchiectasi
mandat
multifacet
manag
consider
heterogen
clinic
featur
comorbid
microbiolog
inflamm
therapeut
respons
cough
remain
import
common
phenotyp
trait
also
key
symptom
definit
bronchiectasi
exacerbationa
major
endpoint
appli
almost
clinic
trial
import
prognost
indic
diseas
progress
chronic
cough
bronchiectasi
exhibit
compar
aetiolog
profil
illustr
high
preval
rate
idiopath
aetiolog
tabl
underscor
shortcom
understand
condit
need
greater
diagnost
resolut
larg
studi
chronic
cough
among
gener
adult
popul
bronchiectasi
identifi
highest
rank
risk
factor
individu
level
accord
ageadjust
odd
ratio
follow
asthma
occup
exposur
dust
fume
airflow
limit
gastrooesophag
reflux
diseas
gord
latter
condit
also
coexist
bronchiectasi
asthma
gord
airflow
limit
ie
copd
recognis
import
comorbid
highlight
potenti
overlap
underli
patholog
cough
bronchiectasi
tabl
associ
risk
occup
exposur
dust
fume
remain
clearli
demonstr
bronchiectasi
case
crossov
studi
link
exacerb
bronchiectasi
fluctuat
outdoor
air
pollut
ad
bodi
literatur
air
qualiti
respiratori
ill
serv
highlight
aetiolog
overlap
condit
central
import
microb
microbi
infect
condit
anoth
common
featur
reflect
epidemiolog
work
commonli
cite
caus
chronic
cough
respiratori
infect
bronchiectasi
classifi
postinfect
tabl
observ
reflect
fundament
role
cough
clearanc
potenti
harm
microb
maintain
lung
homeostasi
highlight
clearli
aberr
statu
bronchiectasi
though
infecti
caus
cough
gener
remain
unresolv
bacteri
pathogen
includ
bordetella
pertussi
bordetella
parapertussi
mycoplasma
pneumonia
chlamydophila
chlamydia
pneumonia
frequent
identifi
fungi
also
implic
trigger
cough
hypersensit
via
activ
allerg
respons
viral
caus
neural
dysfunct
follow
respiratori
infect
link
aberr
cough
sensitis
persist
beyond
initi
infect
primari
bacteri
speci
identifi
bronchiectasi
includ
haemophilu
influenza
pseudomona
aeruginosa
detect
major
bear
antimicrobi
treatment
choic
import
microb
bronchiectasi
substanti
cultureindepend
analysi
lung
microbiom
illustr
influenc
macrolid
therapi
microbiom
composit
associ
microbi
consortia
import
clinic
outcom
includ
exacerb
work
group
other
extens
characteris
fungal
compon
bronchiectasi
microbiom
mycobiom
highlight
high
frequenc
fungal
sensitis
associ
worsen
diseas
sever
lung
function
exacerb
chronic
cough
microbiom
analysi
appli
paediatr
patient
illustr
increas
abund
commens
taxa
lower
airway
potenti
associ
specif
microbiom
signatur
particular
patient
includ
asthma
bacteri
bronchiti
neurolog
impair
oral
fed
subject
observ
highlight
potenti
characteris
cough
endotyp
base
microbiom
analysi
howev
specif
influenc
microbiom
bronchiectasisassoci
cough
remain
defin
asthma
import
bronchiectasi
comorbid
complic
diagnosi
treatment
particularli
case
asthmabronchiectasi
overlap
syndrom
abo
asthma
howev
exhibit
strong
associ
chronic
cough
notabl
coughvari
asthma
cough
predomin
symptom
strong
predictor
bronchiectasi
cigarett
smoke
signific
risk
factor
chronic
cough
smoke
predispos
howev
chronic
obstruct
pulmonari
diseas
copd
bronchiectasiscopd
overlap
syndrom
bco
smoke
may
therefor
importantli
underli
subtyp
cough
copdassoci
cough
occas
relat
bronchiectasi
eg
bco
aetiolog
distinct
bronchiectasi
includ
immun
dysfunct
primari
ciliari
dyskinesia
allerg
bronchopulmonari
aspergillosi
cystic
fibrosi
bronchiectasi
repres
import
caus
chronic
cough
tabl
rhinosinus
relev
diseas
state
report
chronic
cough
patient
patient
idiopath
bronchiectasi
nasal
section
associ
rhinosinus
trigger
excess
cough
perpetu
chronic
diseas
state
relev
bronchiectasi
coexist
rhinosinus
associ
increas
exacerb
high
rate
allergi
given
observ
associ
particular
cough
phenotyp
driven
rhinosinus
could
repres
one
sever
distinct
cough
subtyp
occur
bronchiectasi
sinobronchi
diseas
associ
cough
bronchiectasi
high
preval
japan
exampl
reflect
geograph
environment
influenc
underli
aetiolog
tabl
known
aetiolog
bronchiectasi
intersect
chronic
cough
influenc
cough
bronchiectasi
remain
unclear
given
lack
dedic
studi
directli
assess
associ
fig
tabl
major
aetiolog
chronic
cough
bronchiectasi
wide
accept
treatment
bronchiectasisassoci
cough
physiotherapi
emphasis
pulmonari
hygien
airway
clearanc
rational
enhanc
mucociliari
escal
consequ
remov
purul
airway
secret
subsequ
reduc
burden
incit
microbi
pathogen
inflamm
initi
work
murray
et
al
demonstr
improv
leicest
cough
questionnair
lcq
score
follow
chest
physiotherapi
use
oscillatori
posit
expiratori
pressur
devic
gener
import
evid
apprais
cochran
review
subject
conclud
overal
posit
effect
albeit
recommend
confirmatori
trial
conduct
support
evid
base
subsequ
studi
support
use
posit
expiratori
pressur
bronchiectasi
improv
cough
mechanist
perspect
use
posit
expiratori
pressur
devic
improv
mucu
transport
cough
contribut
reduct
total
number
inflammatori
cell
seen
respiratori
secret
bronchiectasi
recent
work
shown
posit
impact
highintens
inspiratori
muscl
train
cough
seen
declin
better
lcq
score
post
therapi
suggest
improv
respiratori
muscl
strength
enhanc
respiratori
secret
transport
properti
result
benefici
impact
cough
despit
weak
empir
evid
lack
success
sever
larg
clinic
trial
bronchiectasi
antibiot
remain
therapeut
option
treatment
bronchiectasi
associ
infect
select
patient
disappoint
outcom
seen
clinic
trial
investig
inhal
antibiot
formul
rais
concern
trial
design
well
appreci
diseas
complex
heterogen
concern
surround
use
exacerb
clinic
trial
endpoint
overlook
import
diseas
measur
includ
cough
frequenc
sever
date
macrolid
shown
greatest
promis
treatment
bronchiectasi
demonstr
reduct
exacerb
compar
placebo
howev
select
increas
antibiot
resist
effect
macrolid
cough
observ
studi
macrolid
shown
efficaci
treat
cough
among
patient
without
bronchiectasi
suggest
potenti
suitabl
appropri
target
specif
bronchiectasiscough
subtyp
cough
bronchiectasi
may
benefit
direct
focus
personalis
therapeut
approach
howev
current
guidelin
clinician
support
target
use
macrolid
cough
given
absenc
larger
trial
investig
use
specif
purpos
bronchiectasi
given
observ
role
fungi
bronchiectasi
chronic
cough
antifung
therapi
repres
addit
therapeut
avenu
investig
data
remain
limit
ogawa
et
al
demonstr
posit
effect
lowdos
itraconazol
therapi
effect
pronounc
specif
patient
subgroupssuch
colonis
basidiomycet
fungireinforc
import
microbiolog
target
personalis
approach
like
requir
potenti
applic
antifung
therapeut
bronchiectasi
howev
target
specif
diseas
subtyp
driven
fungal
allergi
ident
incit
fungal
speci
may
critic
import
vitamin
central
modul
innat
adapt
immun
respons
potenti
immunolog
function
vitamin
includ
direct
downregul
proinflammatori
cytokin
direct
upregul
regulatori
cytokin
inhibit
mapk
innat
inflammatori
pathway
major
implic
respiratori
diseas
defici
vitamin
lead
increas
autoimmun
suscept
infect
report
bronchiectasi
patient
uk
associ
higher
frequenc
exacerb
infect
howev
remain
unclear
vitamin
defici
set
associ
consequ
inact
bronchiectasi
earli
bronchiectasi
studi
illustr
favour
outcom
supplement
includ
improv
lcq
suggest
direct
benefit
cough
set
vitamin
supplement
therefor
repres
interest
area
futur
investig
term
therapeut
potenti
bronchiectasi
less
known
role
vitamin
chronic
cough
lower
serum
level
report
children
cough
associ
protect
respiratori
infect
afford
vitamin
supplement
support
togeth
data
support
investig
regard
vitamin
supplement
cough
bronchiectasi
statin
member
pharmaceut
class
primari
indic
lower
serum
cholesterol
statin
exert
power
immunolog
effect
antimicrobi
properti
given
pleiotrop
effect
potenti
therapeut
applic
statin
condit
includ
respiratori
diseas
studi
mechan
statin
exert
effect
bronchiectasi
remain
unclear
signific
improv
seen
lcq
patient
treat
atorvastatin
versu
placebo
improv
occur
associ
reduct
sputum
neutrophil
inflammatori
marker
creactiv
protein
interestingli
improv
cough
observ
patient
colonis
p
aeruginosa
emphasis
potenti
impact
microbiolog
microbiom
composit
treatment
outcom
current
howev
use
statin
recommend
bronchiectasi
treatment
option
given
small
sampl
size
trial
potenti
high
rate
advers
event
treatment
group
inconsist
report
find
convers
use
angiotensinconvert
enzym
ace
inhibitor
induc
cough
burden
aceinhibitorinduc
cough
remain
determin
contribut
bronchiectasi
white
circl
indic
influenc
support
studi
cough
specif
measur
grey
circl
indic
presum
influenc
base
associ
diseas
sever
measur
observ
confirm
chronic
cough
may
applic
bronchiectasi
requir
dedic
investig
given
higher
associ
cardiovascular
diseas
preval
evid
antituss
use
bronchiectasi
lack
potenti
benefit
must
weigh
care
potenti
sputum
retent
could
promot
infect
contrast
antituss
agent
extens
investig
cough
use
repres
therapeut
mainstay
treatment
heighten
cough
reflex
coughsuppress
drug
function
target
either
hypersensitis
central
nervou
system
peripher
receptor
instig
cough
respons
mainli
transient
receptor
potenti
trp
ion
channel
nocicept
sensori
neuron
orchestr
cough
reflex
releas
proinflammatori
neuropeptid
cough
therapi
divid
central
act
agent
opioid
target
neural
sensitis
central
nervou
system
receptor
agonist
target
peripher
receptor
involv
stimul
cough
respons
activ
area
coughsuppress
neuromodul
research
may
relev
bronchiectasi
novel
antituss
therapi
allevi
cough
hypersensit
may
fact
prove
efficaci
set
although
work
requir
central
peripher
neuroimmunolog
trigger
cough
remain
delin
bronchiectasi
clearli
perturb
given
hypersensitis
observ
bronchiectasi
therefor
repres
potenti
target
cough
suppress
therapi
fig
nonpharmacolog
cough
suppress
techniqu
bronchiectasi
also
note
sinc
volit
cough
suppress
encourag
physiotherapi
achiev
effectreduct
cough
symptom
whether
repres
viabl
therapeut
strategi
context
bronchiectasi
remain
robustli
valid
emerg
evid
shown
promis
pharmaceut
nonpharmaceut
approach
select
bronchiectasi
patient
cough
bronchiectasi
exist
prelud
formal
diagnosi
correl
worsen
diseas
despit
clinic
trial
thu
far
focus
exacerb
primari
clinic
endpoint
cough
symptom
cough
frequenc
rare
measur
may
serv
altern
power
clinic
indic
wearabl
technolog
acoust
cough
monitor
enhanc
cough
assess
robustli
captur
symptom
offer
accur
object
holist
altern
selfreport
cough
score
widespread
applic
clinic
trial
longitudin
studi
exacerb
major
focu
bronchiectasi
research
cough
burdensom
symptom
patient
signific
impact
qualiti
life
revisit
assess
cough
clinic
endpoint
perhap
incorpor
enhanc
monitor
via
emerg
wearabl
technolog
may
allow
assess
therapeut
effect
greater
precis
compar
statu
quo
exacerb
rate
selfreport
cough
questionnair
sever
clinic
trial
bronchiectasi
use
questionnair
incorpor
coughrel
section
gener
report
aggreg
symptom
score
propos
reanalysi
trial
data
particularli
evalu
macrolid
inhal
antibiot
may
provid
import
inform
regard
particular
impact
drug
coughspecif
domain
better
understand
cough
subtyp
mechan
bronchiectasi
may
ultim
provid
new
improv
clinic
trial
select
criteria
endpoint
measur
requir
care
assess
bronchiectasi
given
alreadi
mix
outcom
sever
larg
unsuccess
clinic
trial
bronchiectasi
exhibit
heighten
cough
sensitivitiesa
condit
associ
sever
respiratori
diseas
statesmeasur
respons
coughstimul
agent
capsaicin
cough
respons
capsaicin
mediat
via
slowconduct
unmyelin
jugular
ganglia
neuron
nociceptor
may
elev
aberr
inflamm
associ
pulmonari
diseas
activ
sensitis
cough
neural
pathway
observ
associ
cough
diseas
sever
may
reflect
need
clear
excess
secret
caus
infect
elev
cough
sensit
suggest
fundament
chang
cough
physiolog
bronchiectasi
oppos
clear
respons
recurr
infect
inflammatori
cue
cough
respons
bronchiectasi
prime
easili
trigger
lead
enhanc
cough
reflex
contribut
patholog
progress
regard
treatment
cough
direct
caus
alon
may
sole
allevi
symptom
arrest
airway
damag
result
aberr
cough
respons
heighten
cough
sensit
seen
bronchiectasi
associ
sever
notabl
clinic
paramet
includ
durat
bronchiectasi
symptom
worsen
hrct
score
increas
sputum
volum
higher
bronchiectasi
sever
index
bsi
sputum
purul
well
sputum
cultur
posit
p
aeruginosa
prime
exampl
bacteri
promot
cough
bronchiectasi
associ
cough
p
aeruginosa
interest
context
microbi
contribut
distinct
cough
phenotyp
contrast
p
aeruginosacolonis
patient
reduc
cough
symptomolog
appar
exhibit
nontubercul
mycobacteria
ntm
cultur
posit
though
unreport
cough
sensit
statu
ntmcolonis
bronchiectasi
patient
compar
domin
p
aeruginosa
relev
microb
would
interest
comparison
futur
investig
differ
sensit
may
link
differ
microbi
profil
bronchiectasi
support
anim
studi
demonstr
sentinel
coughmedi
nociceptor
sensori
neuron
resid
lung
orchestr
distinct
host
respons
presenc
specif
bacteria
provid
plausibl
framework
emerg
specif
microbedriven
cough
phenotyp
bronchiectasi
role
fungi
bronchiectasi
remain
activ
area
research
group
other
presenc
fungi
particular
genu
aspergillu
clear
clinic
signific
bronchiectasi
associ
spectrum
diseas
phenotyp
rang
chronic
pulmonari
aspergillosi
cpa
asymptomat
colonis
fungal
sensitis
allerg
bronchopulmonari
aspergillosi
abpa
presenc
immunolog
manifest
associ
diseas
sever
lung
function
declin
exacerb
even
appar
stabl
patient
role
fungi
cough
bronchiectasi
remain
fulli
explic
impact
fungaldriven
immun
respons
neuroimmunolog
cough
pathway
potenti
area
futur
work
virus
also
implic
bronchiectasi
remain
precis
defin
role
diseas
influenc
cough
among
report
coronaviru
rhinoviru
influenza
ab
exhibit
higher
preval
exacerb
conclus
associ
virus
cough
remain
confirm
bronchiectasi
howev
establish
relationship
virus
hypersensit
chronic
cough
suggest
area
import
futur
epidemiolog
mechanist
studi
set
bronchiectasi
airway
secret
bronchiectasi
domin
neutrophil
associ
cytokin
includ
neutrophil
elastas
among
neutrophilassoci
product
precis
pathway
immunolog
milieu
drive
cough
set
bronchiectasi
remain
establish
howev
known
neuroimmunolog
pathway
cough
like
involv
pathogenincit
inflammatori
event
like
imping
stimul
peripher
vagal
sensori
nerv
respons
cough
reflex
harbour
mani
immun
receptor
neuron
termin
constant
barrag
inflammatori
signal
bronchiectat
airway
like
trigger
neuron
pathway
would
otherwis
remain
silent
possibl
explain
heighten
cough
hypersensit
observ
bronchiectasi
potenti
establish
central
hypersensitis
via
neuroinflammatori
trigger
fig
like
begin
immunolog
excit
pulmonari
sensori
neuron
microbi
airway
trigger
work
baral
et
al
highlight
role
play
nociceptor
suppress
neutrophil
recruit
observ
import
implic
respect
neutrophil
immunopatholog
seen
bronchiectasi
specif
airway
immun
profil
bronchiectasi
like
direct
consequ
cough
hypersensit
cough
phenotyp
bronchiectasi
recent
group
explor
role
sensitis
allergi
bronchiectasi
identifi
high
level
atop
sensitis
even
stabl
patient
observ
parallel
global
atop
tendenc
patient
chronic
cough
reflect
central
role
fungi
allergen
allerg
respiratori
diseas
cough
predomin
symptom
importantli
work
also
characteris
airway
immun
profil
bronchiectasi
reveal
exist
two
distinct
immunoallertyp
defin
specif
immun
profil
distinct
inflammatori
profil
lung
stabl
bronchiectasi
patient
provid
insight
potenti
inflammatori
promot
cough
hypersensitis
notabl
sever
fungaldriven
proinflammatori
fdpi
immunoallertyp
characteris
proinflammatori
signal
includ
tumour
necrosi
factor
establish
role
potenti
effect
rat
neuron
trp
ion
channel
capsaicin
contribut
airway
hyperrespons
immunolog
characteris
bronchiectasi
airway
influenc
specif
cytokin
pattern
hyperrespons
may
futur
shed
light
neuroinflammatori
pathway
drive
cough
hypersensit
bronchiectasi
cough
bronchiectasi
remark
heterogen
clinic
phenotyp
strong
risk
factor
cough
bronchiectasi
may
view
cough
subtyp
amen
specif
treatment
bronchiectasi
standpoint
cough
ubiquit
symptom
question
whether
specif
cough
phenotyp
merit
particular
attent
treatabl
trait
diseas
import
one
neuron
pathway
cough
driven
inflammatori
mediat
describ
great
detail
remain
fulli
assess
bronchiectasi
emerg
molecular
endophenotyp
bronchiectasi
uncov
microbi
immunolog
diseas
signatur
may
explain
cough
hypersensit
respons
set
confirm
cough
subtyp
bronchiectasi
could
futur
provid
scope
novel
therapeut
approach
target
applic
novel
neuroimmun
therapi
alreadi
develop
chronic
cough
